Royalty Pharma plc
RPRX
$45.55
$0.751.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.78% | 7.90% | 7.71% | 0.05% | -0.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.78% | 7.90% | 7.71% | 0.05% | -0.41% |
| Cost of Revenue | -85.91% | 105.33% | -196.00% | -121.79% | 314.39% |
| Gross Profit | 39.40% | -24.63% | 140.92% | 4,551.33% | -36.13% |
| SG&A Expenses | 180.52% | 108.92% | 370.32% | 92.02% | 14.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.39% | 206.31% | 32.22% | -94.69% | 1,479.41% |
| Operating Income | -0.76% | -41.75% | -16.63% | 824.08% | -41.02% |
| Income Before Tax | 6.45% | -44.91% | -53.37% | 10,243.53% | -53.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.45% | -44.91% | -53.37% | 10,243.53% | -53.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -12.34% | 40.54% | 34.55% | -2,255.39% | 43.50% |
| Net Income | 2.88% | -47.02% | -70.42% | 4,888.47% | -57.88% |
| EBIT | -0.76% | -41.75% | -16.63% | 824.08% | -41.02% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 9.00% | -45.09% | -68.48% | 5,014.95% | -68.11% |
| Normalized Basic EPS | -65.88% | -53.68% | -24.14% | 254.13% | -52.54% |
| EPS Diluted | 9.00% | -45.18% | -68.63% | 5,042.45% | -68.08% |
| Normalized Diluted EPS | -65.88% | -52.66% | -24.42% | 254.61% | -36.41% |
| Average Basic Shares Outstanding | -5.60% | -3.52% | -6.10% | -2.93% | 32.09% |
| Average Diluted Shares Outstanding | -5.60% | -5.59% | -5.80% | -3.24% | -1.41% |
| Dividend Per Share | 4.76% | 4.76% | 4.76% | 4.76% | 5.00% |
| Payout Ratio | -0.02% | 0.91% | 2.32% | -0.98% | 1.49% |